444582-90-5

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-4-(2-CARBOXYPHENYL)PIPERAZINE is used as a key intermediate for the synthesis of pharmaceuticals due to its ability to form a variety of potential drug candidates. Its presence of a BOC protecting group allows for the controlled exposure of reactive amine functionalities, which is essential in the development of new medications.
Used in Organic Synthesis:
In the field of organic synthesis, 1-BOC-4-(2-CARBOXYPHENYL)PIPERAZINE is employed as a building block for creating complex organic molecules. 1-BOC-4-(2-CARBOXYPHENYL)PIPERAZINE's structural features, including the piperazine ring and the 2-carboxyphenyl group, contribute to its versatility in forming diverse chemical entities.
Used in the Synthesis of Biologically Active Compounds:
1-BOC-4-(2-CARBOXYPHENYL)PIPERAZINE is also utilized in the synthesis of biologically active compounds, where its unique structure can be modified to target specific biological pathways or receptors, potentially leading to the discovery of new therapeutic agents.

InChI:InChI=1/C16H22N2O4/c1-16(2,3)22-15(21)18-10-8-17(9-11-18)13-7-5-4-6-12(13)14(19)20/h4-7H,8-11H2,1-3H3,(H,19,20)

Upstream product

• 111373-03-6 2-(piperazin-1-yl)benzonitrile 
• 174855-57-3 tert-butyl 4-(2-formylphenyl)piperazinecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 446831-27-2 2-(piperazin-1-yl)benzoic acid 

Downstream Products

• 1253936-71-8 4-[2-(2-amino-4-trifluoromethyl-phenylcarbamoyl)phenyl]piperazine-1-carboxylic acid tert-butyl ester 
• 1253383-94-6 4-[2-(5-methyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-2-ylcarbamoyl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1253936-72-9 N-(2-amino-4-trifluoromethyl-phenyl)-2-{4-[2-(3,5-dimethyl-pyrazol-1-yl)acetyl]piperazin-1-yl}benzamide 
• 1253936-87-6 2-(3,5-dimethyl-pyrazol-1-yl)-1-{4-[2-(5-trifluoromethyl-1H-benzoimidazol-2-yl)phenyl]piperazin-1-yl}ethanone 
• 444582-00-7 1-tert-butoxycarbonyl-4-[2-((2-methylimidazol-1-yl)methyl)phenyl]piperazine 
• 179250-29-4 1-tert-butoxycarbonyl-4-(2-(imidazol-1-ylmethyl)phenyl)piperazine 
• 209160-88-3 1-t-butoxycarbonyl-4-(2-(methanesulfonyloxymethyl)phenyl)-piperazine 
• 179250-28-3 4-(2-(hydroxymethyl)phenyl)piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

CXCR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CXCR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising the

Synthesis and Structure-Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (Ki = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (Ki = 6600 nM). Sulfonamide 39 (Ki = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (Ki = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (Ki = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.